3,469 Shares in Axon Enterprise, Inc $AXON Bought by Donoghue Forlines LLC

Donoghue Forlines LLC acquired a new stake in Axon Enterprise, Inc (NASDAQ:AXON) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 3,469 shares of the biotechnology company’s stock, valued at approximately $2,872,000. Axon Enterprise comprises approximately 0.8% of Donoghue Forlines LLC’s investment portfolio, making the stock its 24th biggest position.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Hemington Wealth Management increased its stake in shares of Axon Enterprise by 70.8% in the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 17 shares during the last quarter. Whipplewood Advisors LLC grew its holdings in Axon Enterprise by 192.9% during the second quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 27 shares during the period. NewSquare Capital LLC increased its stake in Axon Enterprise by 96.2% in the second quarter. NewSquare Capital LLC now owns 51 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 25 shares in the last quarter. Washington Trust Advisors Inc. raised its holdings in Axon Enterprise by 44.7% in the second quarter. Washington Trust Advisors Inc. now owns 55 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 17 shares during the period. Finally, TCTC Holdings LLC boosted its position in shares of Axon Enterprise by 75.0% during the first quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 24 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Down 2.1%

NASDAQ:AXON opened at $557.29 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The company has a market cap of $43.98 billion, a PE ratio of 137.60, a PEG ratio of 29.49 and a beta of 1.45. Axon Enterprise, Inc has a 52-week low of $469.24 and a 52-week high of $885.91. The stock has a 50-day simple moving average of $706.36 and a 200 day simple moving average of $734.49.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm had revenue of $710.64 million during the quarter, compared to the consensus estimate of $704.83 million. During the same quarter in the previous year, the firm posted $1.45 EPS. The company’s revenue was up 30.6% on a year-over-year basis. On average, sell-side analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on AXON. Zacks Research cut shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. Piper Sandler lowered their price target on Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Wall Street Zen lowered Axon Enterprise from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Axon Enterprise in a research report on Wednesday, October 8th. Finally, Barclays dropped their target price on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Fourteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Axon Enterprise has an average rating of “Moderate Buy” and an average price target of $810.71.

Insider Buying and Selling at Axon Enterprise

In other news, Director Jeri Williams sold 100 shares of the firm’s stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $752.54, for a total value of $75,254.00. Following the completion of the transaction, the director owned 1,416 shares in the company, valued at $1,065,596.64. This trade represents a 6.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $743.64, for a total value of $7,436,400.00. Following the completion of the sale, the chief executive officer directly owned 3,043,982 shares in the company, valued at approximately $2,263,626,774.48. This represents a 0.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 38,622 shares of company stock worth $26,439,364 in the last three months. 5.70% of the stock is currently owned by company insiders.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.